The Supreme Court’s decision in Amgen Inc. v. Sanofi, 143 S. Ct. 1243, 1248 (2023), found that antibody claims defined by their binding and blocking function lacked enablement…. The Supreme Court’s decision relied highly on the unpredictability of the art—scientists cannot always predict how substitutions of even single amino acids will affect the binding and/or blocking function of an antibody. The disclosed methods of identifying species within the scope of the claim were little more than “trial and error.”… The consensus seems to be that Amgen generally forecloses broad genus claims in the biotechnology field. The remaining questions are: Are patent applicants limited to claiming species (e., sequence listings)? What steps may a patent applicant take to obtain broader coverage?
Recent Posts
- The World’s AI Companies Are Killing Trust in the Technology
- SCOTUS Rejects Three-Year Limit on Copyright Damages But Sidesteps Accrual Question
- G+ Communications v. Samsung: The Perils of Being ‘Half-Committed’ to FRAND
- Four Factors to Consider When Deciding Whether to Use Trade Secrets
- The CRISPR Battle Through the Lens of International Patent Harmonization